obesity drug - Robuta Search

https://www.nhpr.org/health/2026-04-22/restrictions-on-obesity-drug-coverage-force-patients-to-pivot Restrictions on obesity drug coverage force patients to pivot | New Hampshire Public Radio Apr 22, 2026 - Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a... new hampshire public obesity drug restrictions coverage force https://whitleylawfirm.com/raleigh/dangerous-drug-lawyer/belvig/ Raleigh Belviq Lawyer | Anti-Obesity Drug Linked to Cases of Cancer Feb 20, 2026 - If you or someone you know has taken Lorcaserin and been diagnosed with cancer, you should speak with a Raleigh Belviq lawyer as soon as possible. anti obesity drug linked raleigh lawyer cases https://www.drugtargetreview.com/innovating-obesity-drug-discovery-trends-challenges-and-translational-strategies/669079.article Innovating Obesity Drug Discovery: Trends, Challenges, and Translational Strategies | Webinar |... Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk. obesity drug trends challenges strategies webinar innovating discovery https://www.statnews.com/pharmalot/2026/04/22/medicare-obesity-drug-pilot-program-experimental-roche-ms-drug/ Pharmalittle: Medicare drops obesity drug pilot, Roche touts MS data | STAT Apr 22, 2026 - Roche presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek FDA approval. obesity drug pharmalittle medicare drops pilot https://www.pharmatutor.org/pharma-news/2026/boehringer-dual-action-obesity-drug-survodutide-shows-strong-weight-loss-and-metabolic-benefits Boehringer’s Dual-Action Obesity Drug Survodutide Shows Strong Weight Loss and Metabolic Benefits Apr 28, 2026 - In a major development in the fight against obesity, Boehringer Ingelheim has announced encouraging results for its experimental drug survodutide, offering new... dual action obesity drug shows strong weight loss metabolic https://www.benefitnews.com/advisers/articles/trumps-obesity-drug-plan-for-medicare-would-cost-insurers-billions Trump's obesity drug plan for Medicare would cost insurers billions | EBA | Employee Benefit News Apr 2, 2026 - Only 4.4% of newly-eligible patients would be covered by the projected $900 million in savings, according to new research. employee benefit news obesity drug would cost trump plan https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/ Weight loss drugs on the horizon: STAT's Obesity Drug Tracker Jun 17, 2025 - Our database tracks the new weight loss drugs that could hit the market, novel mechanisms, and which companies are in the hunt. weight loss drugs horizon stat obesity tracker https://www.statnews.com/2024/09/05/obesity-drug-tracker-amylin-weight-loss-drugs-novo-nordisk-eli-lilly-zealand-pharma/ Obesity drug tracker: Can amylin drugs upend Wegovy, Zepbound? | STAT Sep 5, 2024 - Novo Nordisk and Eli Lilly, makers of blockbuster GLP-1 drugs, test amylin hormone receptor treatments in pursuit of fewer side effects. obesity drug wegovy zepbound tracker amylin drugs https://www.biopharmadive.com/news/foundayo-launch-openai-rosalind-janux-gilead-arcellx/817789/ Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool | BioPharma Dive Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux... obesity pill strong start openai debuts new drug discovery tool https://www.statnews.com/2025/10/16/readout-loud-podcast-clive-meanwell-metsera-obesity/ Readout LOUD: Clive Meanwell on drug pricing, obesity market | STAT Oct 16, 2025 - Meanwell chatted about the evolving obesity drug market, and the continued need for drugs to treat diseases with large prevalence. readout loud drug pricing obesity market clive meanwell https://www.biospace.com/deals/neurocrine-nabs-rare-obesity-disorder-drug-in-surprising-2-9b-soleno-deal Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal - BioSpace Apr 6, 2026 - While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to... 2 9b neurocrine nabs rare obesity https://www.pharmavoice.com/news/amylyx-obesity-drug-pharma-als-bariatric-bedrosian/807702/ Amylyx pins its next hopes on a niche drug in the obesity space | PharmaVoice A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia. space pharmavoice amylyx pins next hopes https://diabetesvoice.org/en/news/clinical-trials-obesity-and-type-2-diabetes-management/ ADA Scientific Sessions: new drug therapies for obesity and type 2 diabetes management - Diabetes... Jul 6, 2023 - Clinical trial findings could be game changers in treating people with obesity and type 2 diabetes and slow this public health crisis. ada scientific sessions type 2 diabetes new drug therapies obesity